Thursday, 15 October 2026European Markets

Euro Surges 14% Against Dollar in 2025 as US Currency Hits Three-Year Low

The euro gained 14% versus the dollar in 2025 as the Bloomberg Dollar Spot Index fell to its lowest level since 2022. The British pound rose 7% against the dollar over the same period, while safe-haven flows pushed the Swiss franc higher amid currency market volatility.

Euro Surges 14% Against Dollar in 2025 as US Currency Hits Three-Year Low
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro has surged 14% against the US dollar in 2025, marking a significant shift in currency markets as the Bloomberg Dollar Spot Index dropped to its lowest level since 2022. The dollar's decline has triggered a multi-year currency realignment affecting European-American trade dynamics.

The British pound gained 7% versus the dollar over the same period, though recent pressure pushed the GBP/EUR rate to €1.13—its weakest since April 2023. Currency analysts forecast further pound weakness, with Jordan Rochester at Mizuho Bank projecting a potential decline below $1.30.

Simon Phillips, Managing Director at No1 Currency, noted mounting pressure on sterling as European currencies strengthen relative to both the dollar and pound. The Swiss franc has attracted safe-haven flows as investors seek stability during the currency market upheaval.

The euro's strength complicates EU-US trade relations at a time when European exporters face competitiveness challenges. A stronger euro makes European goods more expensive for American buyers, potentially widening the trade imbalance between the two economic blocs.

Currency strategists attribute the dollar's weakness to multiple factors affecting US monetary policy and fiscal stability. The realignment has pushed the Bloomberg Dollar Spot Index down materially against major currencies, with analysts tracking the trend.

European Central Bank policymakers now face decisions on whether the euro's appreciation warrants intervention or policy adjustments. The 14% gain against the dollar represents one of the euro's strongest performances in recent years, raising questions about export competitiveness across eurozone economies.

UK gilt markets have shown volatility alongside currency movements, with 30-year yields climbing to 5.21%—the highest since August's 1998-era levels. The pound's dual pressure against both the euro and dollar reflects investor uncertainty about UK fiscal policy and economic outlook.

Market participants are monitoring whether the dollar's weakness marks a sustained trend or temporary adjustment. The currency realignment carries implications for European corporate earnings, cross-border investment flows, and central bank policy coordination between the Federal Reserve and European monetary authorities.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com